New Partnership in Rare Disease: Severe Primary Insulin-like Growth Factor 1 Deficiency (SPIGFD)

Australian based biopharmaceutical company Asteri Pharma Pty Ltd (ASTERI Pharma) is proud to partner with ESTEVE, an international specialty pharmaceutical company headquartered in Spain, to provide continued access to a biologic product for children and adolescents aged 2 to 18 with severe primary insulin-like growth factor 1 deficiency (SPIGFD).

ASTERI Pharma’s partnership with ESTEVE highlights its focus on growth in rare disease treatment and meeting unmet patient needs. 

ASTERI Pharma’s supply, distribution and sublicense agreement will continue to enable access for eligible Australian patients. This first biologic in ASTERI’s portfolio is used for the long-term treatment of growth failure in children and adolescents from 2 to 18 years with confirmed SPIGFD.  It was estimated that up to eighty (80) eligible Australian patients may require ongoing access to this treatment.¹ 

"As a rare disorder, patients with SPIGFD often face difficulties associated with receiving a delayed diagnosis, consequently prolonging treatment initiation with limited access to appropriate therapy. This affects patients’ physical health and overall quality of life,² therefore, increased disease awareness and broader multidisciplinary approaches are critical to improve outcomes. Our partnership with ESTEVE perfectly aligns with our strategy, focused on highly specialised treatments for high unmet medical and patient needs", confirms Benet Irish, Chief Executive Officer (CEO), ASTERI Pharma.

ASTERI Pharma is committed to improving the lives of patients across Australia, New Zealand, and Southeast Asia by bringing hope and access to therapies where needs remain unmet.

For further information, please contact Benet Irish, CEO, ASTERI Pharma 

birish@asteripharma.com     

Phone: 1800 178 402 (AUS) 

About ASTERI PHARMA 

ASTERI Pharma is an Australian-based biopharmaceutical company delivering innovative licensing and distribution solutions to unlock the value of new and emerging medicines for the Australian, ANZ and APAC markets. 

We’re driven by purpose—access for all, integrity in action, and the ambition to reach beyond limits. 

Our focus is on addressing diseases with high unmet need, closing the equity gap, and ensuring patients get faster access to life-changing treatments. 

About ESTEVE

To obtain more information about ESTEVE, visit www.esteve.com. 

References  

1. Pharmaceutical Benefits Scheme (PBS), Public Summary Document – March 2022 PBAC meeting. Available online. [Accessed: November 2025] 

2. Backeljauw PF, Andrews M, Bang P, et al. Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective. Orphanet J Rare Dis. 2023 Oct 7;18(1):312.

Asteri Pharma  Pty Ltd.  Brunswick  VIC  3056.   www.asteripharma.com  

AST-INCX-AU-2250 January 2025